Loading...
Loading...
Synta Pharmaceuticals Corp.
SNTA today announced that the
Company has decided to terminate the Phase 3 GALAXY-2 trial of
ganetespib and docetaxel in the second-line treatment of patients with
advanced non-small cell lung adenocarcinoma. Based on the review of a
pre-planned interim analysis, the study's Independent Data Monitoring
Committee (IDMC) concluded that the addition of ganetespib to docetaxel
is unlikely to demonstrate a statistically significant improvement in
the primary endpoint of overall survival compared to docetaxel alone.
The IDMC noted that the combination of ganetespib and docetaxel was
generally well tolerated in the study, with an adverse event profile
consistent with previous studies combining these agents.
GALAXY-2 is a Phase 3 global, randomized, multi-center
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in